Price
$26.11+7.89%Social Signal Score
Analyst Ratings
24 analystsRevenue
$174.54M+438.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey A. Tangney
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 880
- Beta
- 1.29
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 20.71
Financials
Revenue
$174.54M+438.3%Net Income
$34.73M+488.3%EBITDA
$54.68M+588.9%Free Cash Flow
$91.33M+1078.2%EPS (diluted)
$0.18+453.8%Shares Outstanding (diluted)
187.80M+3.4%Operating Expenses
$105.27MCash & Debt
$713.23MReturn of Capital
$54.20MRevenue by Segment (annual)
$644.86MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $644.86M | $196.05M | $1.05 |
| 2025 | $570.40M | $223.19M | $1.19 |
| 2024 | $475.42M | $147.58M | $0.78 |
| 2023 | $419.05M | $112.82M | $0.58 |
| 2022 | $343.55M | $154.78M | $0.81 |
| 2021 | $206.90M | $50.21M | $0.12 |
| 2020 | $116.39M | $29.74M | $0.06 |
| 2019 | $85.69M | $7.83M | $0.00 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DOCS's reported EPS growth of 127.8% a year over 7 years. Historical EPS growth of 128% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $3.89
- Implied price
- $85.63
- Return from $28.73
- 24.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $42.57 — today's price is already 32.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| 20.0% | 7.8% | 11.5% | 14.8% | 17.8% | 20.5% |
| 25.0% | 12.2% | 16.2% | 19.6% | 22.7% | 25.5% |
| 30.0% | 16.7% | 20.8% | 24.4% | 27.6% | 30.6% |
| 35.0% | 21.2% | 25.5% | 29.2% | 32.5% | 35.6% |
| 40.0% | 25.7% | 30.1% | 34.0% | 37.5% | 40.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (40)
- Newszacks.com·6d ago·Neutral
DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems Doximity expands its AI tools across three major healthcare institutions, bringing clinical decision support and documentation into existing workflows.
View source ↗ - Newsmarketbeat.com·10d ago·Neutral
What Dr. Martens (DOCS) Said on Its H1 Earnings Call Dr. Martens LON: DOCS reported a 9.2% decline in first-half revenue at constant currency as weak boot sales and unusually hot weather weighed on trading, particularly in the U.K. and continental Europe.
View source ↗ - Newsfool.com·13d ago·Positive
Doximity: 3 Key Takeaways for Long-Term Investors 16 of the top 20 pharma companies bought AI search programs. Quarterly active workflow prescribers grew 34% year over year.
View source ↗ - Newsmarketbeat.com·15d ago·Neutral
Doximity Q2 Earnings Call Highlights Doximity NYSE: DOCS reported fiscal second-quarter revenue growth of 4% and raised its full-year outlook, as expanding use of its artificial intelligence tools and improving AI cost efficiency helped the company exceed its guidance.
View source ↗ - News (Marketaux)seekingalpha.com·16d ago·Positive
Doximity outlines FY 2027 revenue of $678M-$683M as AI search reaches 8-figure bookings (NYSE:DOCS) Earnings Call Insights Doximity[+137 characters]
View source ↗ - News (RSS)seekingalpha·16d ago·Neutral
Doximity outlines FY 2027 revenue of $678M-$683M as AI search reaches 8-figure bookings
View source ↗ - News (RSS)seekingalpha·16d ago·Positive
Doximity, Inc. (DOCS) Q2 2027 Earnings Call Transcript
View source ↗ - News (RSS)investing·16d ago·Negative
Doximity earnings analysis: questions answered and next catalysts
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Doximity, Inc. (DOCS) Q2 2027 Earnings Call Transcript Doximity, Inc. ( DOCS ) Q2 2027 Earnings Call November 5, 2026 5:00 PM EST Company Participants Perry Gold - Head of Investor Relations Jeffrey Tangney - Co-Founder, CEO & Chairperson Matthew Sonefeldt - CFO & Principal Financial Officer Conference Call Participants Brian Peterson - Raymond James & Associates, Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Craig Hettenbach - Morgan Stanley, Research Division…
View source ↗ - Newszacks.com·17d ago·Negative
Compared to Estimates, Doximity (DOCS) Q2 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·17d ago·Positive
Doximity (DOCS) Beats Q2 Earnings and Revenue Estimates Doximity (DOCS) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.45 per share a year ago.
View source ↗ - Newszacks.com·19d ago·Neutral
Curious about Doximity (DOCS) Q2 Performance? Explore Wall Street Estimates for Key Metrics Evaluate the expected performance of Doximity (DOCS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - Newszacks.com·24d ago·Neutral
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note Doximity (DOCS) closed the most recent trading day at $33.63, moving 1.81% from the previous trading session.
View source ↗ - Newsgurufocus.com·33d ago·Neutral
Doximity, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOCS Doximity, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOCSPR NewswireNEW YORK, Oct. 20, 2026NEW YORK, Oct. 20,
View source ↗ - Newsbusinesswire.com·33d ago·Positive
Doximity and Wolters Kluwer Sign Partnership to Bring UpToDate to Doximity Ask SAN FRANCISCO & WALTHAM, Mass.--(BUSINESS WIRE)--Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, and Wolters Kluwer Health, today announced that UpToDate's trusted, evidence-based, clinical content will be accessible directly within Doximity's fast-growing AI clinical decision support tool, Ask. In the coming weeks, clinicians at health systems using Doximity and UpToDate will see a…
View source ↗ - Newsgurufocus.com·36d ago·Negative
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 17, 2026NEW YORK, Oct. 17, 2026 /PRNewswire/ --
View source ↗ - Newszacks.com·37d ago·Neutral
Why Doximity (DOCS) Dipped More Than Broader Market Today Doximity (DOCS) closed the most recent trading day at $30.71, moving 2.51% from the previous trading session.
View source ↗ - Newszacks.com·38d ago·Neutral
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care DOCS extends its 13-year partnership with U.S. News, strengthening its role in physician searches, appointment booking and hospital rankings.
View source ↗ - Newsprnewswire.com·39d ago·Negative
Doximity, Inc. (DOCS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Oct. 14, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsprnewswire.com·40d ago·Positive
…ntment booking tools used by over 65 million Americans annually to find and schedule care SAN FRANCISCO and WASHINGTON, Oct. 13, 2026 /PRNewswire/ -- Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced it has extended its 13-year partnership with U.S. News & World Report, the nation's most trusted source of independent healthcare information, rankings and guidance to help patients identify the best care for their needs. The extension reinforces Dox…
View source ↗ - Newszacks.com·48d ago·Neutral
Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing The latest trading day saw Doximity (DOCS) settling at $28.58, representing a +2.33% change from its previous close.
View source ↗ - Newszacks.com·48d ago·Positive
Reasons to Retain Doximity Stock in Your Portfolio for Now DOCS' rapid clinical AI adoption and strong cash generation support its outlook, but tight pharma budgets and AI costs may limit near-term gains.
View source ↗ - News (Marketaux)gurufocus.com·52d ago·Positive
A Look at Doximity Inc (DOCS) After 6.9% Gain -- GF Value $45.85 vs Price $28.34 On September 30, 2026, Doximity[+247 characters]
View source ↗ - Newsprnewswire.com·53d ago·Negative
Doximity, Inc. (DOCS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Sept. 30, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newszacks.com·54d ago·Positive
Doximity (DOCS) Gains As Market Dips: What You Should Know In the latest trading session, Doximity (DOCS) closed at $26.52, marking a +1.22% move from the previous day.
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Top Los Angeles Spine Surgeon Dr. Albert Wong Served as Faculty Leader at Advanced Spine Surgery Cadaver Training Courses for SeaSpine and Globus Renowned neurosurgeon Dr. Albert Wong of DOCS Health served as faculty leader at two hands-on cadaver training courses in 2026, teaching minimally invasive
View source ↗ - Newsgurufocus.com·56d ago·Negative
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Sept. 27, 2026NEW YORK, Sept. 27, 2026 /PRNewswire/ -- Rosen
View source ↗ - Newsbusinesswire.com·61d ago·Neutral
Doximity Named Leading Clinical AI Benchmark in Fireworks' Cross-Industry Index SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has been named a founding partner in the launch of a new Specialized Intelligence Index of leading AI benchmarks compiled by Fireworks, the AI training and inference platform. As part of the launch, Doximity is publishing a new open-source benchmark for measuring clinical-g…
View source ↗ - Newsbusinesswire.com·62d ago·Negative
Securities Fraud Investigation Into Doximity, Inc. (DOCS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON DOXIMITY, INC. (DOCS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY P…
View source ↗ - Newszacks.com·62d ago·Negative
Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing In the closing of the recent trading day, Doximity (DOCS) stood at $26.84, denoting a +2.8% move from the preceding trading day.
View source ↗ - Newsbusinesswire.com·66d ago·Negative
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $DOCS--DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newszacks.com·68d ago·Neutral
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note Doximity (DOCS) closed at $25.81 in the latest trading session, marking a -2.2% move from the prior day.
View source ↗ - Newsgurufocus.com·86d ago·Negative
Doximity Inc (DOCS) Shares Surge 4.5% -- What GF Score of 86 Tells Investors On August 28, 2026, Doximity Inc (DOCS) shares rose 4.5% to a current price of $26.73. This performance occurred amidst a 52-week range of $17.15 to $76.51, ind
View source ↗ - Newszacks.com·90d ago·Positive
Reasons to Retain Doximity Stock in Your Portfolio for Now DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.
View source ↗ - Newsfool.com·96d ago·Neutral
Doximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know. The disposition involved 15,311 shares valued at about $380,000 based on a weighted average price of $24.80 per share. The transaction reduced the insider's direct holdings by 3% following the underlying vesting event.
View source ↗ - News (Marketaux)finance.yahoo.com·106d ago·Positive
Why Doximity Stock Skyrocketed on Friday Shares of Doximity (NYSE</e[+253 characters]
View source ↗ - Newsfool.com·106d ago·Positive
Why Doximity Stock Skyrocketed on Friday Doximity's AI assistant is earning favorable reviews from independent researchers. Customer usage of Doximity's AI services is soaring.
View source ↗ - Newsseekingalpha.com·106d ago·Neutral
Doximity: I Called The Pop Over A Month Ago, But Now Is The Time To Wait (Rating Downgrade) Doximity delivered strong fiscal Q1 2027 results, validating my prior bullish stance on valuation and AI-driven growth. The stock surged over 30% intraday, reflecting the market's recognition of DOCS's evolving business model and earnings strength. DOCS is transforming physician searches into a new commercial marketplace, leveraging AI Search to monetize real-time physician intent.
View source ↗ - Newsmarketbeat.com·106d ago·Neutral
Doximity Q1 Earnings Call Highlights Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.
View source ↗ - 4chan /biz/biz·107d ago·Neutral
DOCS up 80% AH
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $0.42 per share
Typical surprise +4.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.36 vs $0.35beat
- Thu, Aug 6$0.29 vs $0.30miss
- Wed, May 13$0.26 vs $0.28miss
- Thu, Feb 5$0.46 vs $0.44beat
- Thu, Nov 6$0.45 vs $0.38beat
- Thu, Aug 7$0.36 vs $0.30beat
Estimates and results for DOCS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DOCS officers and directors.
- Bought
- —
- Sold
- $1.6m
0 trades
16 trades
- Sitaram Siddharthsold
- Cabral Timothy Ssold
- Wampler Kira Scherersold
- Sitaram Siddharthsold
- Wampler Kira Scherersold
- Yang Watkin Phoebe L.sold
- Sitaram Siddharthsold
- Wampler Kira Scherersold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Jonathan Jacksonhouse · IL01 · disclosed Dec 8, 2025 (32d later)Sell$15,001 - $50,000
- Jonathan Jacksonhouse · IL01 · disclosed Sep 24, 2025 (30d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
